Zobrazeno 1 - 10
of 16
pro vyhledávání: '"Manuel Galan-Gutierrez"'
Autor:
Jose Manuel Dodero-Anillo, Inmaculada Concepcion Lozano-Cuadra, Esmeralda Rios-Sanchez, Maria Jose Pedrosa-Martinez, Jose Carlos Ruiz-Carrascosa, Manuel Galan-Gutierrez, Jose Carlos Armario-Hita
Publikováno v:
Life, Vol 12, Iss 12, p 2075 (2022)
In our clinical experience, more than half of patients do not present a complete response to biologic drugs, or drug loses its efficacy over time. Plasma determinations of drug and anti-drug antibodies levels are an objective tool for optimisation in
Externí odkaz:
https://doaj.org/article/5b3adc15830e447fbb271e318dc1c61a
Publikováno v:
Dermatology Reports, Vol 3, Iss 2, Pp e31-e31 (2011)
We report a case of a 66-year-old male who developed an itchy eruption while taking an antihypertonic drug containing eprosartan and hydrochlorothiacide after sun exposure. The lesions resembled a lichenoid appearance that was confirmed by the histol
Externí odkaz:
https://doaj.org/article/5a6e9a41a5a34cefa0fcf78544595e17
Autor:
Ricardo Ruiz-Villaverde, Lourdes Rodriguez Fernandez-Freire, Pilar Font-Ugalde, Manuel Galan-Gutierrez
Publikováno v:
Journal of Clinical Medicine; Volume 11; Issue 17; Pages: 5098
Tildrakizumab (TIL) binds selectively to the p19 subunit of interleukin 23. Its introduction has managed to increase the levels of efficacy, safety (improving that previously presented by the anti-IL-12/23 class) and survival. Retrospective analysis
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9a8d55391cdf1e8b54fb064a01b55262
https://hdl.handle.net/10668/21343
https://hdl.handle.net/10668/21343
Autor:
Ricardo Ruiz-Villaverde, Lourdes Rodriguez-Fernandez-Freire, Marta Cebolla-Verdugo, Alvaro Prados-Carmona, Carlos Hernández-Montoya, José Carlos Armario-Hita, Manuel Galán-Gutiérrez
Publikováno v:
Life, Vol 14, Iss 3, p 281 (2024)
Introduction: Psoriasis, a chronic inflammatory skin disease, affects 2–10% of the population globally. Bimekizumab (BMK), a monoclonal antibody targeting IL-17, is a dual inhibitor of IL17 A and F that has shown efficacy in treating moderate to se
Externí odkaz:
https://doaj.org/article/8be822c4dc184b10bd295ffbd6afa83b
Autor:
Alfonso, Rodríguez-Bujaldón, Carmen, Vazquez-Bayo, Rafael, Jimenez-Puya, Manuel, Galan-Gutierrez, José, Moreno-Gimenez, Alfonso, Rodriguez-Garcia, Jesus, Tercedor, Antonio, Velez-Garcia
Publikováno v:
Pediatric Dermatology. 25:444-448
Lentigines, electrocardiographic abnormalities, ocular hypertelorism, pulmonary stenosis, abnormalities of genitalia, retarded growth, and deafness syndrome (multiple lentigines syndrome) is most often characterized by multiple lentigines and cardiac
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c77ba3556d2db3d6cc45971a4b34e4c4
https://doi.org/10.1111/j.1525-1470.2008.00734.x
https://doi.org/10.1111/j.1525-1470.2008.00734.x
Autor:
David Martín-Enguix, Ricardo Ruiz-Villaverde, Manuel Galán-Gutiérrez, Ana María Cabrerizo-Carvajal
Publikováno v:
Atención Primaria, Vol 55, Iss 4, Pp 102586- (2023)
Externí odkaz:
https://doaj.org/article/4821101dc5054741845b8ab65ecc70c9
Publikováno v:
Acta Dermatovenerologica Croatica
Volume 22
Issue 3
Volume 22
Issue 3
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od_______951::e33925aa2ddea88c2f59eb33cf79f576
https://hrcak.srce.hr/file/187070
https://hrcak.srce.hr/file/187070
Autor:
Fiorella Vasquez Chinchay, Manuel Galán-Gutiérrez, Jose C. Armario-Hita, Amalia Pérez-Gil, Ricardo Ruiz-Villaverde, Lourdes Rodriguez-Fernandez-Freire
Publikováno v:
F1000Research, Vol 11 (2022)
Background: Psoriasis is a chronic inflammatory disease which can impact quality of life. In the past decade multiple biologic treatments have been released with encouraging results. Guselkumab is a monoclonal antibody targeting IL-23p19. Multiple ra
Externí odkaz:
https://doaj.org/article/407b086b973448d79f9c3720c708bd7d
Publikováno v:
Australian family physician. 40(10)
A man, 35 years of age, with an unremarkable past medical history, attended after developing purplish nodules on the left arm. The nodules were in a linear distribution and had developed during recent months after a minor initial injury. The nodules
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::20dfcde0fc352f945a18e95348368be5
https://pubmed.ncbi.nlm.nih.gov/22003484
https://pubmed.ncbi.nlm.nih.gov/22003484
Autor:
Ricardo Ruiz-Villaverde, Lourdes Rodriguez-Fernandez-Freire, Amalia Pérez-Gil, Pilar Font-Ugalde, Manuel Galán-Gutiérrez
Publikováno v:
Life, Vol 12, Iss 11, p 1883 (2022)
Introduction. Risankizumab is a humanized monoclonal antibody of the immunoglobulin G1 (IgG1) type that binds selectively, and with high affinity, to the p19 subunit of interleukin-23 (IL-23), resulting in the inhibition of inflammation and clinical
Externí odkaz:
https://doaj.org/article/1a9fd6d5f9224841aa9efe41d2646a74